Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

Delayed Quote. Delayed  - 09/30 05:35:27 pm
1643 GBp   -0.27%
09/30DJGLAXOSMITHKLINE : to Pay $20 Million to Settle SEC Bribery Probe
09/30 GlaxoSmithKline to pay $20 million to settle U.S. foreign bribery..
09/30DJGLAXOSMITHKLINE : to Pay $20 Million to Settle SEC Bribery Probe
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M GBP Estimates in M GBP
Fiscal Period December 201320142015201620172018
Sales26 50523 00623 92327 00728 35629 531
Operating income (EBITDA)8 8838 0457 0289 1609 75610 276
Operating profit (EBIT)8 0156 5945 7297 1417 8198 459
Pre-Tax Profit (EBT)6 6472 96810 5264 0205 8286 691
Net income5 6282 7568 4222 6843 9844 747
P/E ratio14,624,37,9735,721,418,4
EPS (GBp )11156,717246,076,789,2
Dividend per Share (GBp )78,080,080,080,180,180,7
Yield4,84%5,81%5,83%4,87%4,87%4,91%
Reference price (GBp )1611.513761373164316431643
Announcement Date02/05/2014
12:00pm
02/04/2015
03:18pm
02/03/2016
12:00pm
---
Finances - Leverage
Actuals in M GBP Estimates in M GBP
Fiscal Period December 201320142015201620172018
Debt12 64514 37710 72713 48213 07912 154
Finance------
Operating income (EBITDA)8 8838 0457 0289 1609 75610 276
Leverage
(Debt/EBITDA)
1,42x1,79x1,53x1,47x1,34x1,18x
Capital Expenditure1 1881 1881 3801 6581 5531 546
Book Value Per Share (BVPS)146 PNC87,6 PNC106 PNC69,8 PNC55,5 PNC83,1 PNC
Cash Flow per Share149 PNC108 PNC53,2 PNC111 PNC137 PNC146 PNC
Announcement Date02/05/2014
12:00pm
02/04/2015
03:18pm
02/03/2016
12:00pm
---
Balance Sheet Analysis
Assessed data source :
© 2016 Thomson Reuters
Advertisement
Financial Ratios

Size 2016e 2017e
Capitalization 80 105 M GBP -
Entreprise Value (EV) 93 587 M GBP 93 184 M GBP
Valuation 2016e 2017e
P/E ratio (Price / EPS) 35,7x 21,4x
Capitalization / Revenue 2,97x 2,82x
EV / Revenue 3,47x 3,29x
EV / EBITDA 10,2x 9,55x
Yield (DPS / Price) 4,87% 4,87%
Price to book (Price / BVPS) 23,5x 29,6x
Profitability 2016e 2017e
Operating Margin (EBIT / Sales) 26,4% 27,6%
operating Leverage (Delta EBIT / Delta Sales) 1,91x 1,90x
Net Margin (Net Profit / Revenue) 9,94% 14,1%
ROA (Net Profit / Asset) 7,82% 9,58%
ROE (Net Profit / Equities) 111% 191%
Rate of Dividend 174% 104%
Balance Sheet Analysis 2016e 2017e
CAPEX / Sales   6,14% 5,48%
Cash Flow / Sales 20,0% 23,6%
Capital Intensity (Assets / Sales) 1,27x 1,47x
Financial Leverage (Net Debt / EBITDA) 1,47x 1,34x
Price Earning Ratio Help 
The blue ligne is the average P/E ratio (without estimates)
EPS & Dividend